<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font6" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
<text top="41" left="55" width="254" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Current Controlled Trials in Cardiovascular Medicine 2005, 6 :15<i>Current Controlled Trials in Cardiovascular Medicine</i></text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://cvm.controlled-trials.com/content/6/1/15</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="104" segment_no="14" tag_type="text">Page 5 of 9<b>6</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="105" segment_no="15" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">Once drinking well, diabetic patients will be restarted on</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">their original preoperative diabetic regimens (oral agents</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">and/or insulin therapy). The treatment of diabetes during<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">this study will be closely monitored in collaboration with</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">an endocrinologist specializing in the management of</text>
<text top="145" left="55" width="37" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">diabetes.</text>
<text top="169" left="55" width="78" height="9" font="font5" id="p1_t11" reading_order_no="8" segment_no="5" tag_type="title">Primary Outcomes</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">The primary endpoint of this study will be to assess</text>
<text top="192" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">whether the addition of clopidogrel to aspirin reduces</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">intimal hyperplasia in saphenous vein grafts 12 months<i><b>Primary Outcomes</b></i></text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="6" tag_type="text">after bypass surgery, as assessed by IVUS. Patients will</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="6" tag_type="text">undergo IVUS imaging 12 months post-CABG, and the</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="6" tag_type="text">average intimal area in the proximal 40 mm of one vein</text>
<text top="251" left="55" width="138" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="6" tag_type="text">graft per patient will be assessed.</text>
<text top="275" left="55" width="89" height="9" font="font5" id="p1_t19" reading_order_no="16" segment_no="7" tag_type="title">Secondary Outcomes</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="8" tag_type="text">At the time of intravascular ultrasound, coronary and graft</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="8" tag_type="text">angiography will also be performed to assess vein graft</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="8" tag_type="text">patency and areas of stenosis. Although this trial will not<i><b>Secondary Outcomes</b></i></text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="8" tag_type="text">be sufficiently powered for such a purpose, this data will</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="8" tag_type="text">be obtained whilst gathering information pertaining to</text>
<text top="345" left="55" width="91" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="8" tag_type="text">the primary outcome.</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="9" tag_type="text">Endpoints related to safety will also be documented, both</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="9" tag_type="text">at the time of surgery as well as during the one year of</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="9" tag_type="text">study drug administration. After surgery, data will be</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="9" tag_type="text">recorded regarding chest tube blood loss, blood product</text>
<text top="416" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="9" tag_type="text">transfusions, bleeding requiring tube thoracostomy or</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t31" reading_order_no="28" segment_no="9" tag_type="text">sternal re-opening, perioperative MI, and gastrointestinal</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="9" tag_type="text">complications. Complete blood counts (CBC) will assess</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="9" tag_type="text">the hemoglobin level in the immediate postoperative</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="9" tag_type="text">period and during the one year follow-up. In addition, the</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="9" tag_type="text">incidence of major adverse cardiovascular events follow-</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="9" tag_type="text">ing CABG (mortality, MI, cerebrovascular accident, hospi-</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="9" tag_type="text">talization for coronary ischemia, need for coronary</text>
<text top="510" left="55" width="129" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="9" tag_type="text">intervention) will be recorded.</text>
<text top="533" left="55" width="65" height="9" font="font5" id="p1_t39" reading_order_no="36" segment_no="11" tag_type="title">IVUS Procedure</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="12" tag_type="text">Intravascular ultrasound will be used to assess the area of</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="12" tag_type="text">intimal hyperplasia present in saphenous vein grafts at 12</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="12" tag_type="text">months after surgery. IVUS differs from angiography by<i><b>IVUS Procedure</b></i></text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="12" tag_type="text">providing cross-sectional images of both the vessel wall</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="12" tag_type="text">and lumen with high resolution. The process of intimal</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="12" tag_type="text">hyperplasia is easily detectable and quantifiable by IVUS,</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="12" tag_type="text">but may completely escape visualization by angiography.</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="12" tag_type="text">At one year following CABG, vein graft intimal hyperpla-</text>
<text top="639" left="55" width="105" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="12" tag_type="text">sia is universally present.</text>
<text top="662" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="13" tag_type="text">Efforts will be made to schedule all patients at 52 Â± 2</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="13" tag_type="text">weeks from the day of randomization (Figure 1). The</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="13" tag_type="text">IVUS procedure will first start with angiography of the</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="13" tag_type="text">native coronary arteries and the coronary bypass grafts.</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="13" tag_type="text">This will allow assessment of the progression of native<a href="">(Figure 1). </a>The</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="13" tag_type="text">coronary artery atherosclerosis (both in grafted and non-</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="3" tag_type="text">grafted vessels). Patency of all bypass grafts will be scored</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="3" tag_type="text">using 1) the Fitzgibbon method [14] and 2) the TIMI clas-</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">sification [48]. Patency of the coronary arteries will be</text>
<text top="122" left="313" width="124" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">assessed by the TIMI method.</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="4" tag_type="text">IVUS studies will be performed using a 40 MHz imaging<a href=""> [14] and</a> 2) the TIMI clas-</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="4" tag_type="text">catheter (Atlantis Â® SR Pro, Boston Scientific). This catheter<a href=""> [48]. Paten</a>cy of the coronary arteries will be</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="4" tag_type="text">is a monorail system and has 6F guiding catheter compat-</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="4" tag_type="text">ibility. All IVUS imaging will be done with the administra-</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="4" tag_type="text">tion of unfractionated heparin (70 units per kg, minimum</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">4000 units) before the introduction of the guidewire into</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">a vein graft. Each patient will have at least two vein grafts</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">implanted at the time of surgery. However, imaging of</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">more than one graft is not clinically advisable for safety</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="4" tag_type="text">and practical reasons. In order to minimize bias, the car-</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="4" tag_type="text">diologist performing the IVUS procedure will be blinded</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="4" tag_type="text">to the treatment allocation, and the selection of the SVG</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="4" tag_type="text">for IVUS imaging will be randomized. For this purpose, a</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="4" tag_type="text">sequence randomization scheme (based on the number</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">of vein grafts) will produce a random sequence of num-</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">bers for each patient, such as "2, 1 and 3". These numbers</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">will correspond to the position of the proximal anastomo-</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">sis of each SVG on the ascending aorta (by increasing</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">number from cranial to caudal, starting from 1). The graft</text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">whose random number is produced first will be selected</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">for intubation with the IVUS catheter, unless 1) this par-</text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text">ticular graft showed more than 50% stenosis on the selec-</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">tive angiography performed immediately prior, or 2)</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="4" tag_type="text">access to this graft is technically difficult (graft tortuosity,</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="4" tag_type="text">difficult graft intubation). If any of the above two</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="4" tag_type="text">instances is encountered, the graft with the next number</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="4" tag_type="text">in the randomization sequence will instead be selected for</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="4" tag_type="text">IVUS, and so on. Graft exclusion for whatever basis (either</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="4" tag_type="text">because &gt;50% stenosis or technically difficult access) will</text>
<text top="486" left="313" width="176" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="4" tag_type="text">be recorded for all patients in each group.</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="10" tag_type="text">Once the randomized graft selection has been completed,</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="10" tag_type="text">the actual IVUS procedure will take place. Intracoronary</text>
<text top="531" left="313" width="241" height="13" font="font4" id="p1_t91" reading_order_no="88" segment_no="10" tag_type="text">nitroglycerin (200 Âµ g) will be given before advancing the</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="10" tag_type="text">IVUS catheter, and a 6F guiding catheter will be used to</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="10" tag_type="text">engage the vein graft. Then, a 0.014" coronary angioplasty</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="text">guidewire will be advanced distally through the vein graft</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="10" tag_type="text">and positioned into the native coronary artery. The IVUS</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="10" tag_type="text">catheter will then be advanced into the graft at least 50</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="10" tag_type="text">mm beyond the aorto-ostial anastomosis. The guiding</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="10" tag_type="text">catheter will then be disengaged to ensure visualization of</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="10" tag_type="text">the aorto-ostial anastomosis on pullback. This is essential</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="10" tag_type="text">because the aorto-ostial anastomosis will be the only</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="10" tag_type="text">landmark available to assure measurements of the proxi-</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">mal portion of each graft are comparable between groups.</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">IVUS imaging will be done using a validated motorized</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">pullback device at 0.5 mm/sec. Each study will be</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">recorded on a separate S-VHS videotape. Only one quality</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="10" tag_type="text">pullback will be needed per graft, but a second pullback</text>
</page>
</pdf2xml>
